UNION CITY, Calif.,
Oct. 16, 2015 /PRNewswire/
-- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company
manufacturing point-of-care instruments and consumables for the
medical, research, and veterinary markets, has scheduled a
conference call to discuss its financial results for the second
quarter fiscal year 2016, ended September
30, 2015. The call will be at 4:15
p.m. ET on Tuesday, October
27, 2015. The Company will report financial results
for the second quarter fiscal year 2016 after the market closes on
Tuesday, October 27, 2015.
Participants can dial (877) 317-6789 or (412) 317-6789 to access
the conference call, or can listen via a live Internet web cast,
which is available in the Investor Relations section of the
Company's website at www.abaxis.com. A replay of the call is
available by visiting www.abaxis.com for the next 30 days or by
calling (877) 344-7529 or (412) 317-0088, confirmation code
10074428, through November 3,
2015.
About Abaxis
Abaxis, Inc. is a worldwide developer, manufacturer and marketer of
portable blood analysis systems that are used in a broad range of
medical specialties in human or veterinary patient care to provide
clinicians with rapid blood constituent measurements. Our
mission is to improve the efficiency of care delivery to and the
quality of life of patients in the medical and veterinary
markets. We provide leading edge technology, tools and
services that support best medical practices, enabling physicians
and veterinarians to respond to the health needs of their clients
at the point of care while operating economical and profitable
practices. For more information, visit
http://www.abaxis.com.
Contact:
|
Clint
Severson
|
Lytham Partners,
LLC
|
|
Chief Executive
Officer
|
Joe Dorame, Joe Diaz
& Robert Blum
|
|
Abaxis,
Inc.
|
602-889-9700
|
|
510-675-6500
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abaxis-to-report-second-quarter-fiscal-year-2016-financial-results-on-tuesday-october-27-2015-300161030.html
SOURCE Abaxis, Inc.